Aviva kicks off £350m share buyback after profit jump and bigger dividend
6 March 2026

Aviva kicks off £350m share buyback after profit jump and bigger dividend

London, March 6, 2026, 09:46 GMT

  • Aviva will launch a £350 million share buyback on Friday, following a 25% jump in its 2025 operating profit.
  • The insurer bumped up its final dividend, now at 26.2 pence per share.
  • Results got a boost from the Direct Line deal, plus higher premiums and stronger wealth flows.

Aviva kicked off a £350 million share buyback on Friday, coming right after the British insurer posted a 25% surge in annual operating profit and raised its final dividend. The company credited the profit rise to its tie-up with Direct Line, along with higher insurance premiums and solid wealth inflows. Medium-term targets, set out in November, remain unchanged.

Timing’s key here—UK insurers aren’t getting graded on growth narratives these days, but on how much they return to shareholders. When a buyback comes back on the table post-deal, it’s more than a catchphrase: management is putting out the message that capital’s back in play.

The deal drops just as investors are weighing whether Aviva can absorb Direct Line and still keep a lid on pricing in motor and home—a space where claims costs can turn fast. Legal & General and Phoenix Group, two other UK income-heavy players, are in a similar spot; when cash generation slips, it usually hits their valuations quickly.

Aviva posted a jump in operating profit to £2,203 million for 2025, up from £1,767 million the previous year. Operating earnings per share climbed 17% to 56.0 pence. The insurer logged an IFRS return on equity of 17.5% and put its Solvency II shareholder cover ratio at 180%, a key regulatory capital metric. “We are commencing a £350 million buyback,” group chief executive Amanda Blanc said, as the company also declared a final dividend of 26.2 pence per share.

Aviva laid out its buyback plan, with Citigroup Global Markets set as broker—trading on its own discretion. The company expects the repurchases to kick off March 6 and wrap by Aug. 6. Shares acquired will end up with Aviva and then be cancelled, trimming the outstanding count, the firm said.

Blanc, in a different investor update, said Aviva hit its Group 2026 targets a year ahead of schedule. She also pointed to efforts to “unlock value from Direct Line” and to keep growing in wealth and advice. aviva.com

Aviva’s 2025 outlook makes one point clear: the Direct Line acquisition is now central to its narrative. It stands as the largest transaction under Blanc, pivotal to convincing investors the group can bulk up in personal lines without letting expenses balloon.

Aviva highlighted its wealth division, calling out momentum in a segment where more UK savers are moving cash into long-term products. The company favors this part of the business—it usually requires less capital than underwriting and can help cushion earnings during periods of higher claims.

Even so, the downside isn’t new. A tough stretch for weather claims, rising repair bills, or competitors pushing prices lower could all tighten margins in motor and home insurance—even if premium volumes remain elevated.

Execution risk looms, too. Fumbled integration — whether it’s systems, pricing, or distribution — could easily wipe out planned savings, leading to setbacks instead. Regulators, meanwhile, will scrutinize capital buffers and customer outcomes as the larger group settles in.

Aviva’s investor calendar points to two key dates ahead: the annual general meeting lands on May 6, followed by a first-quarter trading update due May 14.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Xylem

NYSE: XYL 94 / 100
#2 BUY

AerCap

NYSE: AER 92 / 100
#3 BUY ON WEAKNESS

Visa

NYSE: V 89 / 100
#4 BUY IN TRANCHES

Lennox

NYSE: LII 87 / 100
#5 ACCUMULATE

UPS

NYSE: UPS 84 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Zealand Pharma A/S shares plunge as petrelintide results trail Lilly in obesity race
Previous Story

Zealand Pharma A/S shares plunge as petrelintide results trail Lilly in obesity race

Gaxos.ai Stock Jumps After America First Defense Wins Navy License for Counter-Drone System
Next Story

Gaxos.ai Stock Jumps After America First Defense Wins Navy License for Counter-Drone System